Author

A. Krippner-Heidenreich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

O. Heidenreich· 2 shared A. Adamo· 1 shared A. Ptasinska· 1 shared A. Worker· 1 shared B. A. van der Reijden· 1 shared B. M. H. Heuts· 1 shared C. Bonifer· 1 shared D. Gilissen· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

O. Heidenreich

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

S. Arza-Apalategi, B. M. H. Heuts, S. M. Bergevoet, R. Meering, D. Gilissen, P. W. T. C. Jansen, A. Krippner-Heidenreich, P. J. M. Valk, M. Vermeulen, O. Heidenreich, T. Haferlach, J. H. Jansen, J. H. A. Martens, B. A. van der Reijden

The paper identifies HMX3 as a critical vulnerability in MECOM-negative KMT2A::MLLT3 AML, showing it promotes proliferation and blocks differentiation.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology

Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

S. G. Kellaway, S. Potluri, P. Keane, H. Blair, P. S. Chin, A. Ptasinska, A. Worker, L. Ames, A. Adamo, D. J. Coleman, N. Khan, S. Assi, A. Krippner-Heidenreich, M. Raghavan, P. N. Cockerill, , C. Bonifer

This study identifies VEGF and IL-5 signalling pathways as aberrantly activated in t(8;21) leukemic stem cells, enabling their growth and relapse.

bioRxiv · Mar 10, 2023Cancer Biology